Zilarta CT Tablets (Azilsartan + Chlorthalidone )

• Composition :
  Each tablet contains Azilsartan equivalent to AzilsartanMedoxomil 40mg + Chlorthalidone 12.5mg
• Indications :
  Indications: Treatment of mild to moderate hypertension
• Pharmacodynamics :
  It is selectively antagonises the effects of angiotensin II by blocking its binding to the AT1receptor in multiple tissues.Azilsartan is a highly selective antagonist for the AT1 receptor, it exhibits a greater affinity for the AT1 receptor compared with the AT2 receptor. Chlorthalidone is a long-acting oral diuretic with anti-hypertensive activity. It acts on distal convoluted tubule of the nephron. Its diuretic effects lead to decreased extracellular fluid volume, plasma volume, cardiac output, glomerular filtration rate and renal plasma flow.
• Dosage and administration :
  One once tablet, once a day in the morning.
• Contraindications :
  Hypersensitivity to the active substance(s) or to any of the excipients.Anuria, Do not co-administer aliskiren-containing products with Azilsartanin patients withdiabetes. Chlorthalidone- Should be used with caution in patients with renal disease or with impairedhepatic function, Periodic determination of the BUN and serum creatinine are indicated, due to possibility of progression of renal damage.
• Precautions and warnings :
  In patients with an activated renin-angiotensin-aldosterone system (RAAS), such as volume- and/or salt-depleted patients, can cause excessive hypotension. Correct volume or salt depletion prior to administration. In patients with renal artery stenosis, may cause renal failure. Monitor renal function in patients with renal impairment. Consider discontinuing with progressive renal impairment. Chlorthalidone should be used with caution in severe renal disease. Chlorthalidone produces diuresis with increased excretion of sodium and chloride. The site of action appears to be the cortical diluting segment of the ascending limb of Henle's loop of the nephron. The diuretic effects of chlorthalildone lead to decreased extracellular fluid volume, plasma volume, cardiac output, total exchangeable sodium, glomerular filtration rate, and renal plasma flow.
• Use in pregnancy, lactation & pediatrics :
  Teratogenic Effects, Pregnancy Categories C (first trimester) and D (second and third trimesters).Discontinue the tablet as soon aspregnancy is detected, There are no adequate and well-controlled studies in nursing women and children
• Drug interactions :
  The antihypertensive effect of angiotensin II receptor antagonists, including azilsartan, may beattenuated by NSAIDs, including selective COX-2 inhibitors.No clinically significant drug interactions have been observed in studies of azilsartanmedoxomil or azilsartan given with amlodipine, antacids, chlorthalidone, digoxin, fluconazole, glyburide, ketoconazole, metformin, pioglitazone, and warfarin.
• Adverse reactions :
  The most commonly reported adverse events are diarrhoea, asthenia, muscle spasm, dizziness and fatigue.
• Therapy Area :
  Anti-Hypertensives